Compare BioNano Genomics Inc (BNGO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Mesoblast Limited — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Mesoblast Limited trades at $16.79 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 161.8× BioNano Genomics Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MESO | |
|---|---|---|
Market Cap | $13.66M | $2.21B |
Sector | Health | Technology |
52-Week High | $4.92 | $20.96 |
52-Week Low | $1.06 | $12.88 |
Enterprise Value | $16.26M | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
